Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Take a Look at your new club in A.C.
http://www.scores-ac.com/?utm_source=dad&utm_medium=email&utm_content=19766361&utm_campaign=20131029_nightlife
I hear the Detroit Club is Fantastic.
Blackcat
Fellow Shareholder, I think it is time to give a BID SHOUT OUT TO SETH SHAW for staying focus on delivering for all TAUG Shareholders. This guy is an incredible CEO for TAUG. We will do over 2 Million shares today. The MM are having a tuff time trading this stock the last few days. The short must be 5 million shares. Next Stop $.10 with the size short out with the MM.
Blackcat7717
Correction 600 shareholders.
Blackcat
To all that might want to buy here! I would recommend that you try to tease the seller at $.03 to reduce his sell order by placing your buy order between $.025 - $.029. Time is running out. Tic Toc Tic Toc. This seller wants $.03, he is the only supply of stock at theses prices in any quanity. I beleive he has more than the 88,000 shares he is showing at $.03.
The only 3 other large shareholders of free trading stock I know of are, Wildcat, badman, and myself. All long term players.
This seller at $.03 may not know what the company is currently doing. It may also be a person who was paid for services rendered with stock a long time ago. I do not know how many he has left. I do know I bought from this seller at least 2 million shares between $.025 and $.03 just in the last 6 months.
You might be asking yourself why am I being so generous with my suggestion and not purchase any more for myself. The reason is I am in it for the very Long Term. I do not want to own more than 5% of any company.
My position is to large to sell on the open market.I would not sell even at $.25 It would put to much pressure on SCRH. If the company in the future does an underwriting at $1.00 or higher, I will sell half of my position. By me not being a seller until $1.00 also reduces the float on free trading shares. This is good for all of you.The S/O currently are 165 Million. Mr. Gans has control of 115 Million or more .Between Badman, Wildcat, and myself approx. 25 Million. That leaves 25 Million share free trading stock with at least 300 shareholders. Financials could be out soon. It is more important that they are current than the numbers.
Blackcat
Badman, it looks like the seller is back on SCRH at $.03. Completed my order of 2800 shares at .03. The seller is offering 97,200 T $.03 today. I do not know if this cleans him up. You might be wise to limit your order at $.025 or less GTC. You and I are the only buyers. At this time the Company has no clue who it is.
Blackcat
Badman. Picked up a small 7200 shares at $.03 2300 left to buy.
Blackcat
Johnny8544, I want you to remember only one thing when you are investing in any stock. "THE STOCK TRADING VOLUME NEVER LIES" Why do you think the average 90 day volume has been so high?
Some people are smarter than we are and closer to the company than we are and they have been buying all these cheap shares from those shareholders that are loyal to Dr. Harnoy. It is simple they sell TAUG and buy shares in the PRIVATE COMPANY ITL. Do you think for a moment all this buying is for investors that need a tax loss?
If there was no buying from $.05 all the way down to $.015, the company would be trading at $.00001. I do not need inside information to see that TAUG is under SERIOUS ACCUMULATION. Let'stalk at year end and compare notes. By the time Jan.1,2014 roles around and you look back you will see the SP higher and see how someone else made a great deal of money. We have a HUGH advantagewith this penny stock. That advantage is we can TRUST Seth Shaw to do the right thing for TAUG & his shareholders.
After the smoke clears and we are left with only Loyal (TAUG) SETH SHAW Shareholder,Then and only then will we will see advancement in the S/P.
Blackcat7717
Zalicuslicious, Not only am I still positive, I added 3 million shares to my already HUGH position. Fasten your seat belts.
My average now is $.06.
Blackcat
Badman, Just bought 49,000 shares at $.03 to round off my position. It is your time at bat do not be afraid. If the seller
at $.02 wants to sell at .03 & .04 we can take them all and start selling at $.17 to .75. for a Capital Gain next year.
Blackcat
It looks like the financials are being worked on. The reason for the delay was the opening of SCORES in Atlantic City I am sure. My guess is less than 2 weeks before reporting with the SEC. The question is are they filing the year end 2012 and all 3 Quarters to get them current in 2013. I think yes!
I hear from friends of mine in Detroit that the club will open
soon and is outstanding.
The only supply of stock that I can see on Level 2 is at $.04
about 200,000 shares $8000.00 dollars. After that we go to $.07.
This company for the first time since Mr. Gans has taken over shows signs that it is now fully committed to keep sharesholders current with all information. I would not be surprise if we get a shareholders letter within 30-45 days.
Blackcat
Badman I will be moving up my order for 49,000 soon to $0.024 It looks like the seller at .02 is done.
Blackcat7717
Tauriga Sciences Inc. Retains International Law Firm Nixon Peabody LLP as Legal Advisor for the Structuring of Future Business Transactions. (Reuters) Mon Oct 14, 2013 8:01am EDT
NEW YORK, Oct. 14, 2013 (GLOBE NEWSWIRE) -- Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and evaluating potentially lucrative acquisition targets in an industry agnostic manner, has today announced the retention of the international law firm Nixon Peabody LLP ("Nixon Peabody) to advise the Company on both the structuring future business transactions and the evaluation of intellectual property ("IP"). The Company is currently contemplating and negotiating potential business opportunities and is pleased to have retained such an experienced law firm with vast resources as Nixon Peabody. The Company anticipates that future business opportunities and transactions may include but are not limited to: purchase orders from existing license agreement, entering into new license agreements, establishment of joint venture partnerships, direct investments (equity stakes), and merger and acquisition activity. The Company will disclose to shareholders, via a press release, when and if a contemplated business transaction is consummated.
About Tauriga Sciences, Inc.:
Tauriga Sciences, Inc. is a a diversified company focused on generating profitable revenues through license agreements and evaluating potentially lucrative acquisition targets in an industry agnostic manner. The mission of the Company is to acquire and build a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company's business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. The Company's new corporate website can be found at www.tauriga.com.
About NIXON PEABODY LLP
Nixon Peabody LLP is a full-service law firm that helps clients navigate complex challenges in litigation, real estate, corporate law, and finance. With more than 600 attorneys throughout the U.S., Europe, and Asia, the firm has the ability to handle matters anywhere in the world, ensuring that clients get the right attorneys, right where they need them. Our focus is on listening to our clients and working collaboratively to help them achieve their business objectives. We have the experience to anticipate and capture opportunities, prepare for and manage risks, and forecast and overcome obstacles (www.nixonpeabody.com).
Blackcat
badman, Nice to have you back posting. I am trying confirm a time
line for posting of the next 3 financial quarters. So far it looks like 2 weeks from now. The lawyers have the fiqures so it should be soon. After that a letter to shareholders with an update. Also, I here the SCRH business web site is being worked on as we speak for an updated version.
P.S. I do not know if that seller is still around at .025 or not. I do not know if he is complete. Put a bid up for 10,000 shares GTC $.025 to find out. That is me at $.022 for 49,000. If we both get hit we will know.
Blackcat7717
To all investors: More than 3000 patrons attended the Grand opening of SCORES at the Taj Mahal on September 12, 2013. Financials will be coming soon for the company to be current. A friend of mine attended the opening. $$$$$$$$$$$$$$$$$
Blackcat
Scores opening in Taj Mahal in Atlantic City on Thursday September 12,2013. $25 Million + cost on Adult Complex.
http://www.philly.com/philly/news/new_jersey/20130912_Scores_gives_A_C__casino_sex_appeal.html
Blackcat
pennythinker33 As large investor with more than $200,000 dollars invested in TAUG I understand your frustration.
I would like you to consider holding off attacking ITL for 45 days. Remember, when you attack ITL you attack TAUG as well. TAUG owns 9% of ITL. It was DR. Har-noy who tossed the first stone. We all get that. However, Seth Shaw has been working his butt off
to build a new company. He saved us from going under and now is in the building process. Seth Shaw is focused on 100% of the company to succeed. When we make money on TAUG, it will be done based on SETH SHAW'S effort not DR.Har-Noy. Try to think of ITL as icing on the cake or a tax loss. Focus on the success of TAUG not ITL. Any negative posts hurts TAUG. Investors might not invest in TAUG reading these negative posts on ITL.
If you are an investor in TAUG, you do yourself harm by posting all these negative comments from the past.
Speech is Silver Silence is Golden.
Blackcat
Hi badman, Have an enjoyable trip. I hear the year end and 2 quarters will be posted soon. A shareholder update I hope will follow after A/C opens.
Blackcat7717
Hi badman, Have an enjoyable trip. I hear the year end and 2 quarters will be posted soon. A shareholder update I hope will follow after A/C opens.
Blackcat7717
Hi badman, Have an enjoyable trip. I hear the year end and 2 quarters will be posted soon. A shareholder update I hope will follow after A/C opens.
Blackcat7717
Badman, Providence Journal is reporting Sept. 12 2013 Opening of Scores in the Taj Mahal. I got a call from a shareholder who lives in R.I. He said he saw a GREAT article in the Journal on SCORES in this morning paper. August 27,2013
I do not know if you notice a large seller between .018- .025 cents. Myself and friends of mine have purchased about 2.5 million shares from this one seller during the last two months. before we started to buy these shares we saw one day the seller showed 3.2 million shares for sale at .025. He sold them as low as .018. I believe there is 700,000 shares left. This block taken out will help the stock in the long run.
Blackcat7717
Panther14565
Now that is solid info I can take to the bank.
I do not think TAUG officials are planning to take a tax loss any time soon.
Blackcat
CFO2 The next time we talk you will be complaining about paying taxes on your Capital Gain. LOL
Blackcat
CFO2
My guess is 3 months or less we will be at $.10 again. Remember for Seth Shaw to save our A** and not let hte company go out of business, the company had to increase the number of shares outstanding to make some deals. Market Cap at $.10 (during Dr. Harnoy) will equal to the all time high of $.30 shares increased from 100 Million to 300 Million (after Dr. Harnoy). Those of you that are using the CHARTS I do not think you take this into account. We still do not here anything from Dr. Harnoy. HMMMM I wonder why?
P.S. I was able to get my average down to $.05 from $.15 and still buying.
Blackcat
Hi Johnny8544, With all do respect, you have no idea about the big picture. Read my post over and over.
Blackcat
Johnny8544, The jury is out still on Dr. Harnoy. This is the reason he withdrew from doing business with Taug. Dr. Harnoy could not produce any answer or time table on getting the hold removed from the FDA. He is a private company now with no SEC supervision. The less he tells us the happier he will be. The trials in Bangkok should have started by now. We do not get any info from Oceanlow1 or anyone who beliefs in DR. Harnoy. You have to ask yourself why is that? History will prove that Seth Shaw is the only one that saved us from going out of business. Notice the volume everyday. We are taking everyone out. We want every investor to go in the direction they find best for them. I am 100% focused on TAUG. I will make a great deal of money. Our only enemy is time.
Blackcat
To all that are invested in TAUG. Read & Print my post #2179.
Tape it to your computer and read it every day. Until we get this done we are going to stay in this range.
Blackcat
Johnny8544,CHANGE IN BENEFICIAL OWNERSHIP" MEANS AN INCREASE OR DECREASE IN THE NUMBER OF SHARES THE BENEFICIAL OWNER HAS.
THE 30 DAY EXTENTION WAS JUST FOR TECH. REASONS. TAUG HAS MORE THAN ENOUGH MONEY NOW. THEY ARE LOOKING AT OTHER ACQUISITION.
BLACKCAT
I guess no one read my last post!
Blackcat
Hello everyone, I just cannot get this message across to all of you. I have bought a ton of stock down at these prices. This stock will not go up until we clean up all the seller's that are investing elsewhere. Once that is done we will be moving higher. Hang in there guy's
Blackcat
Clueless1 Those investor that own TAUG & ITL are still selling TAUG and buying ITL shares.For now this will hurt the price of TAUG. However this is temporary. If ITL is raising more money to start the trials in Bangkok it will not matter. We own 9% of ITL. It is like borrowing money from your sister and giving it to your brother. In the end it will all work out.I am focusing on TAUG fundamentals. The fundamentals are fine. I see nothing but buying from the Officers & Directors. Remember these to companies went through a terrible divorce. If you know anything about a divorce, it take time for things to heal. Let us pray that Dr. Harnoy has something real and starts the trials in Bangkok to assist TAUG in the future. Seth Shaw announces everything he is doing for his shareholders. Nothing yet from Dr. Harnoy.The Jury is still out.
Blackcat
Plague, Was that June 4, 2007 ? Six years ago.
Blackcat
Badman,If we are lucky we will see the year end financials before the end of July. It will take more time to do the 10K vs. 10Q.
Blackcat7717
Year End figures could be out by the end of July. I think SCRH financials will be current by the time the AC Club opens.
Blackcat
http://immunovativetherapies.webs.com/apps/blog/
Dr. Michael Har-Noy and Immunovative Therapies Develop Unique Cancer Drugs
Posted by anonymous on July 13, 2013 at 3:55 AM comments (0)
Physicianshave been largely unsuccessful in treating patients with metastatic cancer.Medical scientists have made significant advances in early cancer diagnosis andprevention in the past two decades, but they have made relatively few inroadsin treating advanced malignant disease.
The principle problem with current cancer therapies is that they usually cannoteradicate every cancer cell. Furthermore, as in the case of chemotherapy andradiation, they are often very toxic to the body and have unacceptable sideeffects. A young, daring biotech company named Immunovative Therapies Ltd.,founded by Dr. Michael Har-Noy, is hoping to vastly improve the way cancer istreated. Immunovative Therapies is now testing groundbreaking drugs that enableone’s own immune system to kill metastatic cells.
Dr.Michael Har-Noy, founder and CEO of Immunovative Therapies,describes their flagship product, AlloStim™, as a biological drug synthesizedfrom precursors found in the circulation of a normal donor. These precursorsare then purified, differentiated, expanded, and then frozen untilneeded. When infused into a cancer patient’s blood, these unique cellscreate an inflammatory environment which disarms tumor avoidancemechanisms. Because AlloStim™ cells are intentionally mis-matched and areseen by the host as foreign, the patient’s own immune system “wakes up” to thesedanger signals and is able to both reject the AlloStim™ cells and kill thetumor cells.
Dr.Michael Har-Noy, using this patented “Mirror EffectTM” described above, hasessentially produced the tumor-killing effect of a successful allogeneic bonemarrow transplant without exposing the patient to the lethal problem of graftversus host disease.
Preliminary Phase I/II datashows that AlloStim™ has a remarkable anti-tumor effect across a wide varietyof metastatic cancers. A Phase II/III trial of AlloStim™ in the treatment ofmetastatic breast cancer will hopefully be under way soon in Thailand. Withtheir unique biologic drugs, Immunovative Therapies and Dr. Michael Har-Noy may be on the verge of creating an entire new field ofoncology.
Dr. Michael Har-Noy of Immunovative Therapies, Changing The Way Cancer Is Treated
Posted by anonymous on July 4, 2013 at 6:10 AM comments (0)
Over the last few decades, medicine hasmade tremendous strides in the treatment of infectious disease, cardiovascularillness, and other life-threatening conditions. However, most metastatic canceris treated today with similar methods that were used twenty years ago, namely acombination of surgery, chemotherapy, and radiation. Aside from sporadic use ofmonoclonal antibodies and individualized cancer vaccines, cancer therapy hasnot advanced significantly in recent years.
Immunovative Therapies Ltd., a small,relatively new biotech company in Israel, is using a novel approach to treatmetastatic tumors. Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies,is developing unique drugs that “wake-up” a patient’s immune system and enableit to attack and kill metastatic cells. Dr. Michael Har-Noy’s work may usher ina whole new era of cancer therapy.
Dr. Michael Har-Noy, a world-renowned andrecognized immunologist and scientist, spent many years at Hadassah MedicalCenter in Israel studying bone marrow transplant patients and defining theimmunologic characteristics of successful transplant patients that did notdevelop graft versus host disease. At Immunovative Therapies, Dr. MichaelHar-Noy has used this information to formulate complex cellular-based compoundsthat, when administered to a cancer patient, provoke the patient’s own immunesystem to attack the administered drug and in the process, attack the tumor aswell.
At Immunovative Therapies, Dr. MichaelHar-Noy has developed and is testing three prototype compounds; AlloStim™,CryoStim™, and AlloVax™. As opposed to the anti-tumor effect of a bone marrowtransplant, these drugs provoke a tumor-killing immune response that has nopotential for toxicity, as it is the patient’s own immune system, and not aforeign transplant, that initiates the tumor-killing process.
Medical scientists have as yet been unableto consistently stimulate a patient’s immune system to seek out and killcancerous cells. Dr. Michael Har-Noy of Immunovative Therapies appears to havediscovered a way to facilitate this process, and in doing so may sooncompletely change the way cancer is treated.
Blackcat
Immunovative Therapies Updated July 2013 Immunovative Therapies Receives $300,000 Grant From Misgav Venture.
AcceleratorImmunovative Therapies is developing unique and groundbreaking cancer treatments. The company’s founder and CEO, Dr. Michael Har-Noy has spent most of his career pioneering these novel new treatments. Because of the great promise of this work, Dr. Michael Har-Noy’s Immunovative Therapies was able to secure a $300,000 grant from the Misgav Venture Accelerator, a member of the Israel technological incubator program. The Misgav Venture Accelerator transforms brilliant life science ideas into great businesses, thereby facilitating scientific research and making significant improvements in the worlds of medicine and science.
Blackcat
Clueless, The trials in Carlsbad Calif. were conducted 3 years ago. The trials we are looking for are in Bangkok Thialand.
Blackcat
New York July 9,2013 ITL
Immunovative Therapies Ltd. Introduces a Revolutionary Approach To Cancer Treatment
Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, a biotech company in Israel, discusses a unique approach to cancer treatment, in which its cellular-based drugs stimulate the host immune system to target and kill malignant cells.
NEW YORK, July 9, 2013 /PRNewswire-iReach/ -- The most promising way to develop curative treatment that eliminates every cancer cell in a patient, says Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies Ltd., would be by vaccinating the patient against the tumor. The patient's own immune system, if correctly stimulated and manipulated, is capable of killing every last cancer cell. The concept of vaccine-based immune treatment of cancer is based on the body's own natural defense mechanism, which guards it against many diseases. Vaccine immunotherapy has been shown to be an extremely effective treatment strategy for prevention of numerous potentially lethal infectious diseases.
Vaccines consisting of either killed or attenuated pathogens have revolutionized the public health system by thwarting the progression of many deadly infectious diseases, such as smallpox, poliomyelitis, rabies, diphtheria, cholera, typhoid fever, bubonic plague, measles, mumps, tetanus, and hepatitis B. Dr. Michael Har-Noy believes that the application of vaccination based therapy to cancer could similarly revolutionize cancer therapy.
However, Dr. Michael Har-Noy of Immunovative Therapies indicates that synthesizing effective cancer vaccines has proven to be much more difficult than developing vaccines for prevention of infectious diseases. Attempts to create successful immunotherapies in the form of cancer vaccines, despite decades of research and experimental trials, have yet to demonstrate significant curative potential in patients with malignant tumors.
The one dramatic exception to the failure of immunotherapy to produce significant tumor killing effects in cancer patients is the immunologic response that occurs in patients undergoing allogenic bone marrow/stem cell transplantation (BMT). The BMT is a proven curative therapy for certain hematological malignancies and also has shown some effectiveness in the treatment of solid tumors. The curative effect of the BMT is caused by the transplanted immune cells, which are derived from a healthy, tissue matched donor. The immune mediated anti-tumor activity of these transplanted cells is termed the graft vs. tumor (GVT) effect. At Immunovative Therapies, this mechanism has been analyzed in detail, and Immunovative Therapies has used the powerful cancer-killing GVT effect as the basis for the synthesis of an entirely new class of oncologic drugs.
Dr. Michael Har-Noy describes the GVT mechanism as the most powerful and most efficient tumor-killing process ever identified in the treatment of human cancer. Unfortunately, these same immune system T-cells which control the GVT effect also can cause an often lethal complication known as graft versus host disease (GVHD). This side effect occurs because the transplanted T-cells recognize both the normal and tumor cells of the recipient as foreign material and attack them both indiscriminately. Therefore, despite the fact that a BMT can eradicate solid as well as hematologic cancers, the often lethal toxicity of GVHD has prevented the wide spread application of BMT as a cancer treatment.
The powerful GVT immune mechanism observed in BMT recipients is capable of disabling a tumor's immunoavoidance capability, thus resulting in complete eradication of the cancer in many instances. The GVT effect has been shown to be able to cure cancer patients with large tumors, including patients with malignancies unresponsive to chemotherapy, radiation and other types of immunologic treatments.
Immunovative Therapies has developed a line of biologic products, based upon completely proprietary technology, which is engineered to produce, in a cancer patient, the same anti-tumor effect that has been shown to be curative in allogenic bone marrow transplant (BMT) procedures but without the potentially lethal toxicity associated with it. Dr. Michael Har-Noy of Immunovative Therapies hopes to soon begin a Phase II/III trial of these drugs in metastatic breast cancer patients.
About: Immunovative Therapies Ltd. is a biotech company in Israel. Under the direction of its founder and CEO, Dr. Michael Har-Noy, the company is developing and testing revolutionary new cancer treatments that, when brought to market, will likely spawn a new field of oncology.
Media Contact: Bethany Franklin, Optimizeup.com, 1-800-701-6787, support@optimizeup.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Immunovative Therapies Ltd.
RELATED LINKS
http://re.vu/immunovativetherapies
Does anyone out there hear anything about the the start of any trials from Dr. Harnoy? They were to start in April. Does anyone know what price we would have to pay to buy ITL stock. I have a group investors that indicated an interest in buy ITL shares. My investors keep asking me if the trials have started. My answer is always the same I do not know. These investors as a group invested 1 Million dollars in IMUN at .10. (10 Million shares)
Blackcat